Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 12, Issue 3, Pages 379-399Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.12.3.379
Keywords
antiMRSA; beta-lactam; BAL9141; cephalosporin; cethromycin; dalbavancin; daptomycin; garenoxacin; gemifloxacin; glycopeptide; glycylcycline; ketolide; MRSA; oritavancin; oxazolidinone; PRSP; RWJ-54428; sitafloxacin; telithromycin; tigecycline; VRE
Categories
Ask authors/readers for more resources
With the continuing development of clinical drug resistance among bacteria and the advent of resistance to the recently released agents quinupristin-dalfopristin and linezolid, the need for new, effective agents to treat multidrug-resistant Gram-positive infections remains important. This review focuses on agents presently in clinical development for the treatment of serious multidrug-resistant staphylococcal, enterococcal and pneumococcal infections, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and penicillin-resistant Streptococcus pneumoniae. Agents to be discussed that affect the prokaryotic cell wall include the antimethicillin-resistant S. aureus cephalosporins BAL9141 and RWJ-54428, the glycopeptides oritavancin and dalbavancin and the lipopeptide daptomycin. Topoisomerase inhibitors include the fluoroquinolones gemifloxacin, sitafloxacin and garenoxacin. Protein synthesis inhibitors are represented by the ketolides telithromycin and cethromycin, the oxazolidinones and the glycylcycline tigecycline. Although each of these compounds has demonstrated antibacterial activity against antibiotic-resistant pathogens, their final regulatory approval will depend on an acceptable clinical safety profile.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available